120 related articles for article (PubMed ID: 32020530)
1. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients.
Groenland SL; van Eerden RAG; Verheijen RB; de Vries N; Thijssen B; Rosing H; Beijnen JH; Koolen SLW; Mathijssen RHJ; Huitema ADR; Steeghs N;
Clin Pharmacokinet; 2020 Jul; 59(7):941-948. PubMed ID: 32020530
[TBL] [Abstract][Full Text] [Related]
2. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Krens SD; Lubberman FJE; van Egmond M; Jansman FGA; Burger DM; Hamberg P; Vervenne WL; Gelderblom H; van der Graaf WTA; Desar IME; van Herpen CML; van Erp NP
Int J Cancer; 2021 Jun; 148(11):2799-2806. PubMed ID: 33428771
[TBL] [Abstract][Full Text] [Related]
3. Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.
Verheijen RB; Bins S; Mathijssen RH; Lolkema MP; van Doorn L; Schellens JH; Beijnen JH; Langenberg MH; Huitema AD; Steeghs N;
Clin Cancer Res; 2016 Dec; 22(23):5738-5746. PubMed ID: 27470967
[TBL] [Abstract][Full Text] [Related]
4. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.
Krens SD; Mulder SF; van Erp NP
Cancer Chemother Pharmacol; 2022 Feb; 89(2):271-274. PubMed ID: 34853912
[TBL] [Abstract][Full Text] [Related]
5. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
[TBL] [Abstract][Full Text] [Related]
6. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
Verheijen RB; Swart LE; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1171-1178. PubMed ID: 29051995
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C; Puszkiel A; Boudou-Rouquette P; De Percin S; Alexandre J; Berge M; Ulmann G; Blanchet B; Batista R; Goldwasser F; Thomas Schoemann A
Cancer Chemother Pharmacol; 2024 Feb; 93(2):169-175. PubMed ID: 37620675
[TBL] [Abstract][Full Text] [Related]
8. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
de Wit D; van Erp NP; den Hartigh J; Wolterbeek R; den Hollander-van Deursen M; Labots M; Guchelaar HJ; Verheul HM; Gelderblom H
Ther Drug Monit; 2015 Jun; 37(3):331-8. PubMed ID: 25271729
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
Kumar R; Knick VB; Rudolph SK; Johnson JH; Crosby RM; Crouthamel MC; Hopper TM; Miller CG; Harrington LE; Onori JA; Mullin RJ; Gilmer TM; Truesdale AT; Epperly AH; Boloor A; Stafford JA; Luttrell DK; Cheung M
Mol Cancer Ther; 2007 Jul; 6(7):2012-21. PubMed ID: 17620431
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
15. Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.
Noda S; Yoshida T; Hira D; Murai R; Tomita K; Tsuru T; Kageyama S; Kawauchi A; Ikeda Y; Morita SY; Terada T
Clin Genitourin Cancer; 2019 Apr; 17(2):e306-e313. PubMed ID: 30598361
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
[TBL] [Abstract][Full Text] [Related]
20. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
Groenland SL; Katz D; Huitema ADR; Steeghs N
BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
